Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, today announced that Dr. Yaron Daniely, President and Chief Executive Officer of Alcobra, will provide a corporate overview at the upcoming BIO CEO & Investor Conference… Read more »

Shares of Alcobra Ltd closed yesterday at $6.21 . ADHD has a 1-year high of $25.44 and a 1-year low of $3.12. The stock’s 50-day moving average is $4.83 and it’s 200-day moving average is $10.39.

On the ratings front, Alcobra has been the subject of a number of recent research reports. In a report issued on November 18, Roth Capital analyst Debjit Chattopadhyay reiterated a Buy rating on ADHD, with a price target of $10, which represents a potential upside of 61.0% from where the stock is currently trading. Separately, on November 17, Aegis Capital’s Yi Chen downgraded the stock to Hold .

Alcobra Ltd is a biopharmaceutical company which engaged in the development and commercialization of its proprietary oral drug candidate, MDX, to treat ADHD and other cognitive dysfunctions including Fragile X Syndrome.